SEARCH

SEARCH BY CITATION

References

  • 1
    Lappin G, Garner RC. The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol 2008; 4: 14991506.
  • 2
    Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2000.
  • 3
    Guideline. Pharmacokinetic Studies in Man. European Medicines Agency, 1987.
  • 4
    Recommendation No 1866. From the 109th meeting recommendations on the Provision of an Absolute Bioavailability Study for all New Chemical Entities. Australian Drug Evaluation Committee (ADEC) Pharmaceutical Subcommittee (PSC) of the Therapeutic Goods Administration (TGA), Department of Health and Ageing, Australian Government (2006).
  • 5
    ICH Topic M 3 (R2). Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2009).
  • 6
    Rowland M. Commentary on ACCP position statement on the use of microdosing in the drug development process. J Clin Pharmacol 2007; 47: 15951596.
  • 7
    Bertino JS, Greenberg HE, Reed MD, American College of Pharmacology. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process. J Clin Pharmacol 2007; 47: 418422.
  • 8
    Sarapa N, Hsyu PH, Lappin G, Garner RC. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 2005; 45: 11981205.
  • 9
    Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006; 80: 203215.
  • 10
    Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 2010; 40: 125131.
  • 11
    Smith DA. The debate is over: accelerator MS provides the route to better drug-development paradigms/protocols. Bioanalysis 2011; 3: 391392.
  • 12
    Xu X, Christopher L, Dueker S, Lohstroh P, Roongta V, Cojocaru L, Keung CF, Humphreys WG, Cao K, Samuel B, Stouffer B, Arnold ME. Achieving regulatory approval: Overcoming bioanalytical challenges in an Onglyza™ Micro-tracer Absolute Bioavailability Study with accelerator mass spectrometry. 12th Annual Land O'Lakes Bioanalytical Conference: Agency and Industry Perspectives on Biomarkers, Bloodspots and Beyond, Merrimac, WI July 11–15, 2011.
  • 13
    Guidance for Industry. Bioanalytical Method Validation. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001.
  • 14
    Dueker SR, Vuong le T, Lohstroh PN, Giacomo JA, Vogel JS. Quantifying exploratory low dose compounds in humans with AMS. Adv Drug Deliv Rev 2010; 63: 518531.
  • 15
    Xu X, Dremers R, Gu H, Christopher L, Su LH, Cojocaru L, Boulton DW, Kirby M, Stouffer B, Humphreys WG, Arnold M. Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding at low concentrations. J Chromatogr B 2012; 889–890: 7786.
  • 16
    Rowland M, Tozer TN. Clinical Pharmacokinetics, Concepts and Applications, 2nd edn. Philadelphia PA: Lea & Febiger, 1989.
  • 17
    Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 10931095.
  • 18
    Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther 2011; 33: 17981808.
  • 19
    United States Prescribing Information for OnglyzaTM (saxagliptin). Bristol-Myers Squibb Company and AstraZeneca Pharmaceuticals LP (Feb. 2011).
  • 20
    Su H, Boulton DW, Barros A Jr, Wang L, Cao K, Bonacorsi SJ Jr, Iyer RA, Humphreys WG, Christopher LJ. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome p450 inhibition/induction profile of saxagliptin in human. Drug Metab Dispos 2012; 40: 13451356.
  • 21
    Shen DD, Kunze KL, Thummel KE. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997; 27: 99127.
  • 22
    Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010; 38: 405414.